Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.09.2021 | Case report

Darbepoetin-alfa/pacritinib/ruxolitinib

Various toxicities and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Alrifai T, et al. MPN-280: Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Male with Heavily Pretreated INT-2 Primary Myelofibrosis. Clinical Lymphoma, Myeloma & Leukemia 21 (Suppl. 1): S359 abstr. MPN-280, Sep 2021. Available from: URL: http://doi.org/10.1016/S2152-2650%2821%2901828-0 [abstract] Alrifai T, et al. MPN-280: Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Male with Heavily Pretreated INT-2 Primary Myelofibrosis. Clinical Lymphoma, Myeloma & Leukemia 21 (Suppl. 1): S359 abstr. MPN-280, Sep 2021. Available from: URL: http://​doi.​org/​10.​1016/​S2152-2650%2821%2901828-0 [abstract]
Metadaten
Titel
Darbepoetin-alfa/pacritinib/ruxolitinib
Various toxicities and lack of efficacy: case report
Publikationsdatum
01.09.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-02088-8

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Dexamethasone

Case report

Gefitinib

Case report

Tozinameran

Case report

Antineoplastics